Randomized Trialhigh evidence
Extended-Release vs Sublingual Buprenorphine in Pregnancy Through 12 Months Post Partum: A Randomized Clinical Trial.
JAMA internal medicine·May 1, 2026·PMID 41837971
Why it mattersExtended-release buprenorphine may improve adherence and reduce illicit opioid use during pregnancy, a critical period for maternal and fetal health, while maintaining a comparable neonatal safety profile.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled